A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving Dialysis

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 922 participants.

Also called NCT01750190

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 922 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01750190
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Chile, Colombia, Hong Kong SAR China, Malaysia, Mexico, New Zealand, Peru, Philippines, Puerto Rico, Singapore, South Korea, Taiwan, Thailand (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01750190. Randomized; quadruple masking; primary purpose treatment. Start 2012-11-05 (actual); primary completion 2018-09-24 (actual). Results posted on 2021-10-01.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving Dialysis
Condition
CKD Anemia
Intervention (Drug)
Roxadustat
Intervention (Drug)
Placebo
Lead sponsor
Kyntra Bio (class: industry)
Collaborator
Astellas Pharma Europe B.V. (class: industry)
Collaborator
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct01750190
Content hash
905c5c6701949c0706ff906f75db4bec6ddd939b9964e38525677f8f5e75f350